Cocrystal Pharma (COCP) vs Psyence Biomedical (PBM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cocrystal Pharma (COCP) has outperformed Psyence Biomedical (PBM) over the past year, losing 14.4% versus a loss of 97.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COCP | PBM |
|---|---|---|
| Share price | $1.07 | $4.97 |
| Market cap | $20.61M | — |
| 1-day change | 0.00% | -2.93% |
| YTD return | +9.18% | -82.59% |
| 1-year return | -14.40% | -97.05% |
| 5-year return | -90.51% | — |
| EPS (TTM) | $-0.76 | $-12.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.03 | $150.78 |
| 52-week low | $0.76 | $1.92 |
| Distance from 52-week high | -47.29% | -96.70% |
| Analyst consensus | none | — |
| Avg. price target upside | +741.12% | — |
| Average volume | 56.00K | 94.85K |
| Shares outstanding | 19.26M | — |
| Employees | 10 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COCP has outperformed PBM by 82.6 percentage points over the past year.
About Cocrystal Pharma
COCP stock →Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
COCP vs PBM FAQ
Which stock has performed better over the past year, COCP or PBM?
COCP returned -14.40% over the past 12 months, compared with -97.05% for PBM (price return, excluding dividends). Past performance does not predict future results.
Are Cocrystal Pharma and Psyence Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.